The Drug Utilisation Sub-Committee of the PBAC has flagged several cancer drugs for review at its next meeting.
The committee says it will look at predicted versus actual use for:
- Lenalidomide for myelodysplastic syndrome;
- Paclitaxel, nanoparticle albumin-bound, for metastatic adenocarcinoma of the pancreas;
- Eculizumab for atypical haemolytic uraemic syndrome (aHUS); and
- Sunitinib and everolimus for metastatic or unresectable, well-differentiated malignant pancreatic neuroendocrine tumour (pNET).
Under the remit of an ‘analysis of multiple medicines in a treatment area’ they will also look at thalidomide, bortezomib, lenalidomide and pomalidomide for multiple myeloma and bevacizumab, cetuximab and panitumumab for metastatic colorectal cancer.